Zynerba Pharmaceuticals — Investor Presentation (June 2018)
42 slides from Zynerba Pharmaceuticals's investor presentation, Jun 7, 2018
Slide 1: Disclaimer
Disclaimer The statements in this presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things relate to the future operations,
Slide 2: Zynerba Pharmaceuticals: A Rare/Near-Rare Neuropsychiatric Company
Two patent protected compounds: ZYN002 (CBD gel) and ZYN001 (THC pro-drug patch) Focused on high unmet medical needs Fragile X syndrome (FXS): ~71K U.S. patients; no approved products Developmental and epileptic encephalopathies (DEE): ~45K U.S. patients Adult refractory focal epilepsy: ~500K U.S. p
Slide 3: Expected 2018 Milestones
4 Expected 2018 Milestones 1Q 2Q 3Q 4Q ZYN002 Fragile X Syndrome FDA meeting 1Q18 DEE Initiate Phase 2 open label study in 1H18 Adult refractory focal epilepsy Initiate new Phase 2B study in 2H18 Present/publish additional data from STAR 2 extension study in 2018 ZYN001 Tourette Syndrome Complete Ph
Slide 4: ZYN002 Cannabidiol (CBD) Gel
First and only patent-protected permeation-enhanced pharmaceutically-produced cannabidiol (CBD) gel formulated for transdermal delivery CBD binds to multiple receptors and may mediate a number of pathways, including the endocannabinoid pathway Patented formulation increases the delivery of CBD throu
Slide 5: Fragile X Syndrome: Preparing for 2018 Pivotal Study
U.S. Orphan Drug Designation for use of CBD as a treatment of Fragile X (Feb. 2016) Positive open label Phase 2 data (Sept. 2017): Achieved primary and numerous secondary endpoints with statistical significance vs. baseline Extremely well tolerated Data accepted for oral presentation at NFXF Interna
Slide 6: Developmental & Epileptic Encephalopathies (DEE): New Phase 2 Program
Third party clinical data show impact of CBD on seizures and behavioral issues in children Patient enrollment in BELIEVE 1 Phase 2 study underway Six month multi-dose study in ~50 DEE patients (3 to <18 years) Primary efficacy assessment: change in seizure frequency Results expected in 2019 7 Develo
Slide 7: Adult Refractory Focal Epilepsy: Phase 2B Anticipated in 2018
STAR 2 data suggest continued improvement in seizure control in adult refractory focal seizure patients receiving ZYN002 through 12 months of open label exposure Presented in Late Breaking poster session at 2018 AAN (April 25, 2018) Learnings from Phase 2 STAR 1 study and open label STAR 2 extension
Slide 8: ZYN001 THC Pro-Drug Patch
9 Patent-protected pharmaceutically-produced D-glyceric acid ester-9-tetrahydrocannabinol (THC) in a transdermal patch ZYN001 is a pro-drug A drug administered in an inactive or less active form, designed to enable more effective delivery, and then converted into a different form through a normal me
Slide 9: Potential for THC in Tourette Syndrome
10 Potential for THC in Tourette Syndrome (TS) Neurodevelopmental disorder characterized by motor / vocal tics Evident in early childhood ~200K U.S. pts have most severe form Up to 1:100 exhibit milder and less complex symptoms Central cannabinoid receptor system believed to play role in Tourette Sy
Slide 10: Expected 2018 Milestones
11 Expected 2018 Milestones 1Q 2Q 3Q 4Q ZYN002 Fragile X Syndrome FDA meeting 1Q18 DEE Initiate Phase 2 open label study in 1H18 Adult refractory focal epilepsy Initiate new Phase 2B study in 2H18 Present/publish additional data from STAR 2 extension study in 2018 ZYN001 Tourette Syndrome Complete P
Slide 11: June 2018 Company Description
June 2018 Dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs
Slide 12: ZYN002 CBD Gel Clinical Program: Fragile X Syndrome
ZYN002 CBD Gel Clinical Program Fragile X Syndrome
Slide 13: The Endocannabinoid System is a Critical Pathway
Rare genetic developmental disability; leading known cause of both inherited intellectual disability and autism spectrum disorder Symptoms linked to deficiencies in the endocannabinoid system ECs form system of neurotransmitters regulating emotional responses, behavioral reactivity to context, socia
Slide 14: Fragile X Syndrome Open Label Phase 2 Trial Design
Maintenance Dosing initiated at CBD 50 mg Daily; may be titrated up to 250 mg daily Screening Titration Weeks 7 to 12 Day 1 to Week 6 Doses of CBD 50 mg, 100 mg, or 250 mg daily 20 patients enrolled Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD (FAB-C) Period 1 Period 2
Slide 15: Positive FAB-C Open Label Phase 2 Efficacy Data: ADAMS
Anxiety, Depression and Mood Scale (ADAMS) total score Improvement vs. baseline (N=20) Changes in Anxiety, Depression and Mood 46% (p<0.0001) ADAMS subscales Improvement vs. baseline (N=20) General Anxiety 54% (p<0.0001) Social Avoidance 53% (p<0.0002) Compulsive Behavior 50% (p=0.0262) Manic/Hypera
Slide 16: Positive FAB-C Open Label Phase 2 Efficacy Data: ABC-CFXS
17 Aberrant Behavior Checklist for Fragile X (ABC-CFXS) subscale Improvement vs. baseline (N=20) Stereotypy: "Repetitive Movements" 59% (p=0.0006) Social Avoidance: "Seeks Isolation" 55% (p=0.0005) Socially Unresponsive/Lethargic: "Does Not Pay Attention" 53% (p=0.0034) Inappropriate Speech: "Repeat
Slide 17: ADAMS Subscales Week 12: Percent Improvement vs. 3rd Party Data
18 Manic/hyperactive Behavior Depressed Mood Social Avoidance General Anxiety Compulsive Behavior Baseline: 9.4 Baseline: 8.1 8.7 Baseline: 2.8 Baseline: 3.0 3.1 Baseline: 10.2 Baseline: 6.9 7.5 Baseline: 10.0 Baseline: 7.9 8.3 Baseline: 2.8 Baseline: 3.0 3.4 * Ligsay, A., Van Dijck, A., Nguyen, D.
Slide 18: ABC-CFXS Subscales Week 12: Percent Improvement vs. 3rd Party Data
19 Irritability Temper Tantrums Hyperactivity Disrupts Group Activities Socially Unresponsive / Lethargic Does Not Pay attention Social Avoidance Seeks Isolation Stereotypy Repetitive Movements Baseline: 18.2 Baseline: 18.9 19.6 Baseline: 14.5 Baseline: 13.9 13.9 Baseline: 8.7 Baseline: 6.6 6.9 Base
Slide 19: Positive FAB-C Open Label Phase 2 Safety Data
20 Very well tolerated, consistent with previously reported clinical data; no SAEs Two sibling patients discontinued due to worsening of pre-existing eczema No drug-related GI events No THC was detected in the plasma 13 patients continued into open label extension; 12 remain as of 6/4/18 Twelve pati
Slide 20: Fragile X Syndrome Pivotal Study Proposed Trial Design
Period 1 14 weeks Period 2 12 months Fragile X Syndrome Pivotal Study Proposed Trial Design* ZYN002 Double-blind, placebo-controlled 21 Treatment Open-label extension ZYN002 250 mg daily 500 mg daily (patient weight based) Placebo Sachets to mirror ZYN002 administration *Note: Subject to change due
Slide 21: ZYN002 in Fragile X Syndrome: Next Steps
22 Expect to begin pivotal trial in pediatric and adolescent patients with FXS mid-year 2018 204 patients from U.S., Australia and New Zealand Key endpoints will assess observable behaviors: ABC-CFXS Top line data expected in 2019 Request pre-NDA meeting after data is available in 2019 to determine
Slide 22: ZYN002 CBD Gel Clinical Program: Developmental Epileptic Encephalopathies (DEE)
ZYN002 CBD Gel Clinical Program Developmental Epileptic Encephalopathies (DEE)
Slide 23: Developmental and Epileptic Encephalopathies
Heterogeneous group of epilepsy syndromes associated with severe cognitive impairment and behavioral disturbances Syndromes involve: Significant developmental impairment (developmental encephalopathies) Regression of developmental progress (epileptic encephalopathies) Often progressive; highly resis
Slide 24: BELIEVE DEE Open Label Phase 2 Study
Period 1 Six months Period 2 12 months BELIEVE 1 DEE Open Label Phase 2 Study Results Expected in 2019 ZYN002 25 *Note: Subject to change due to further regulatory, clinical and other considerations. Weight based dosing from 250 to 500 mg daily Screening Titration 2-3 week taper period Extension Tar
Slide 25: ZYN002 CBD Gel Clinical Program: Adult Refractory Focal Epilepsy
ZYN002 CBD Gel Clinical Program Adult Refractory Focal Epilepsy
Slide 26: Adult Refractory Focal Epilepsy: Phase 2B Anticipated in 2018
STAR 2 data suggest continued improvement in seizure control in adult refractory focal seizure patients receiving ZYN002 through 12 months of open label exposure Learnings from Phase 2 STAR 1 study and open label STAR 2 extension provide input into Phase 2B trial design Expect to initiate ~300 patie
Slide 27: Epilepsy Phase 2 Clinical Study Trial Design
Baseline Assess seizure frequency/type Open-Label Extension Synthetic Transdermal CAnnabidiol for the TReatment of Epilepsy ZYN002 CBD 390 mg daily STAR 2 Trial STAR 1 Trial Dose can be adjusted to: 18 months 12 weeks 8 weeks Randomized (1:1:1), double-blind, placebo-controlled - 188 patients Epilep
Slide 28: STAR 1 Demographics and Baseline Characteristics
Epilepsy Phase 2 Clinical Study Demographics and Baseline Characteristics ZYN002 STAR 1 patients Placebo 195 mg ZYN002 390 mg ZYN002 Total Pts Randomized 63 63 62 188 Sex 43% male 57% female 51% male 49% female 42% male 58% female 45% male 55% female Pts Analyzed for efficacy 63 62 61 186 Pts comple
Slide 29: STAR 1 and STAR 2 Results
Epilepsy Phase 2 Clinical Study STAR 1 and STAR 2 Results Company believes study missed primary endpoint due to bimodal distribution of placebo patient responses : >50% reductions in focal seizures in ~¼ of placebo patients 13 of these 15 patients were female Strong separation from placebo seen at >
Slide 30: Data Presented at 2018 AAN: STAR Efficacy Data
Data Presented at 2018 AAN STAR 2 Efficacy Data 31 Median Percent Change in Seizure Rates at Months 3, 6, 9, and 12 All ZYN002-Treated Patients in STAR 2 ZYN002 STAR 2 results based on data collected through mid-December 2017 and in patients who reported seizure frequency data during the respective
Slide 31: Data Presented at 2018 AAN: STAR Efficacy Data
Data Presented at 2018 AAN STAR 2 Efficacy Data 32 Median Percent Change in Seizure Rates at Months 3, 6, 9, and 12 ZYN002 STAR 2 results based on data collected through mid-December 2017 and in patients who reported seizure frequency data during the respective time period.
Slide 32: Consistent Results at Various Timeframes: Three Months on ZYN002
33 -19% N=56 -14% N=55 -10% N=60 -32% N=56 -31% N=55 -16% N=49 -48% N=49 -38% N=48 Median Percent Change in Seizure Rates Dose Regimen in STAR 1 and STAR 2 STAR 2 results based on data collected through mid-December 2017 and in patients who reported seizure frequency data during the respective time
Slide 33: Consistent Results at Various Timeframes: Six Months on ZYN002
34 -19% N=56 -14% N=55 -10% N=60 -32% N=56 -31% N=55 -16% N=49 -48% N=49 -38% N=48 Median Percent Change in Seizure Rates Dose Regimen in STAR 1 and STAR 2 STAR 2 results based on data collected through mid-December 2017 and in patients who reported seizure frequency data during the respective time
Slide 34: Consistent Results at Various Timeframes: Nine Months on ZYN002
35 -19% N=56 -14% N=55 -10% N=60 -32% N=56 -31% N=55 -16% N=49 -48% N=49 -38% N=48 Median Percent Change in Seizure Rates Dose Regimen in STAR 1 and STAR 2 STAR 2 results based on data collected through mid-December 2017 and in patients who reported seizure frequency data during the respective time
Slide 35: Consistent Results at Various Timeframes: Twelve Months on ZYN002
36 -19% N=56 -14% N=55 -10% N=60 -32% N=56 -31% N=55 -16% N=49 -48% N=49 -38% N=48 Median Percent Change in Seizure Rates Dose Regimen in STAR 1 and STAR 2 STAR 2 results based on data collected through mid-December 2017 and in patients who reported seizure frequency data during the respective time
Slide 36: Consistent Results at Various Timeframes: Fifteen Months on ZYN002
37 -19% N=56 -14% N=55 -10% N=60 -32% N=56 -31% N=55 -16% N=49 -48% N=49 -38% N=48 Median Percent Change in Seizure Rates Dose Regimen in STAR 1 and STAR 2 STAR 2 results based on data collected through mid-December 2017 and in patients who reported seizure frequency data during the respective time
Slide 37: Proposed Phase 2b Study: Adult Refractory Focal Epilepsy
~300 patient double-blind placebo controlled study To be conducted in U.S., Australia and New Zealand Primary endpoint: reduction from baseline in focal seizures 1:1:1 ratio (195 mg: 780 mg: placebo) 38 Learnings from STAR 1 and STAR 2 experience include: Stratified randomization by baseline seizure
Slide 38: Financial Strength
Cash and cash equivalent position of $52.1 million Well capitalized, expect cash to fund operations well into 2019 39 Financial Strength As of March 31, 2018
Slide 39: Scientific Advisors
Elizabeth M. Berry-Kravis, MD, PhD Professor, Department of Pediatrics, Rush Medical College Craig A. Erikson, MD Associate Professor, Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children’s Hospital Randi J. Hagerman, MD Medical Director, UC Davis MIND Institute, Distinguished P
Slide 40: Investor Relations
41 484.581.7505 investorrelations@zynerba.com www.zynerba.com @ZynerbaPharma Zynerba Zynerba Investor Contact Will Roberts, VP, Investor Relations and Corporate Communications 484.581.7489 NASDAQ: ZYNE Analyst Coverage* Ladenburg Thalman: Michael Higgins HC Wainwright: Oren Livnat Cantor Fitzgerald:
Slide 41: Zynerba Pharmaceuticals, June 2018
June 2018 Dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs
Slide 42: Zynerba, June 2018
— ynerba’® Utically-produced cannabinoid treatments for rare and n rare E unmet medical needs June 2018
Zynerba Pharmaceuticals — Investor Presentation (June 2018) on 6ix